|
KMID : 0370220180620060419
|
|
Yakhak Hoeji
2018 Volume.62 No. 6 p.419 ~ p.423
|
|
|
A Review on the 2016 US FDA Botanical Drug Development Guideline Based on Approvals of Veregen and Fulizaq
|
|
Song In-Suk
Hwang Jung-Joong
Lee Jong-Kook
|
|
|
Abstract
|
|
|
|
Botanical products derived from plants have been used for a long time. In the early 2000s, regulation authorities implemented development guidelines for botanical drugs. In US, two botanical drugs, Veregen and Fulizaq, were approved and have been sold in global markets. US Food and Drug Administration (FDA) revised their botanical drug development guideline for industry in 2016 based on the experiences of reviewing botanical New Drug Applications (NDAs) and Investigational New Drug applications (INDs). General approach to botanical drug development has remained unchanged (marketing of botanicals under NDAs, botanical drug development under INDs, INDs for Phase I, II, and III clinical studies) compared to 2004 versions. However, a number of specific recommendations have been modified and several new sections like ‘NDAs for botanical drug products’ have been added especially for late phase development and NDA submission. For local pharmaceutical companies that are developing botanical drugs for worldwide markets, we summarize herein the major issues for the newly updated US FDA botanical guideline based on the review materials of the previously approved two botanical drugs.
|
|
|
KEYWORD
|
|
|
Botanical drug, drug development guideline, Veregen, Fulizaq
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|